Generic Name: fostemsavir

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Entry Inhibitors

Company: ViiV Healthcare

Approval Status: Experimental

Generic Version Available: No

Experimental Code: BMS-663068

Drug Indication

Fostemsavir has not yet been reviewed for inclusion in the DHHS list of recommended HIV treatments.

General Info

Fostemsavir is an experimental HIV medication. It is in a category of HIV medicines called attachment inhibitors. Fostemsavir targets a different step of the viral lifecycle and may be an option for indiviuals with virus that has become highly resistant to other HIV drugs.

ViiV Healthcare filed a new drug application with the Food and Drug Administration (FDA) for fostemsavir approval in December 2019. It was granted FDA fast track and breakthrough therapy designations, which means the agency will facilitate and expedite the development and review of the ARV.

Fostemsavir must be used in combination with other HIV drugs.


Dosing Info:


Side Effects


Other Info

Last Reviewed: December 11, 2019